Key result
Inhaled iloprost therapy improved exercise-induced pulmonary hypertension in a patient with systemic sclerosis-associated interstitial lung disease, as revealed by exercise echocardiography.
Why the study?
It is unclear whether inhaled iloprost is an effective treatment for exercise-induced pulmonary hypertension.
Does inhaled iloprost improve exercise-induced pulmonary hypertension in a patient with systemic sclerosis-associated interstitial lung disease?
Case Report (n=1)
No
Does inhaled iloprost improve exercise-induced pulmonary hypertension in a patient with systemic sclerosis-associated interstitial lung disease?
Inhaled iloprost, evaluated via exercise echocardiography, may be an effective treatment and diagnostic tool for patients with systemic sclerosis-associated interstitial lung disease who have overlapping group 1 and group 3 pulmonary hypertension.
Does not support practice change in SSc-ILD; hypothesis-generating for inhaled iloprost in exercise PH.
Rationale: Inhaled iloprost has been used as a selective pulmonary vasodilator in the treatment of pulmonary arterial hypertension; however, it is unclear whether it is an effective treatment for exercise-induced pulmonary hypertension (PH). Patient concerns: A 66-year-old Japanese woman with systemic sclerosis-associated interstitial lung disease presented with dyspnea, worsening during exertion. Diagnosis: Overlap of exercise-induced PH and group 3 PH. Interventions: Inhaled iloprost was administrated. Outcomes: Exercise echocardiography revealed that inhaled iloprost therapy improved her exercise-induced PH. Conclusion: Exercise echocardiography and inhaled iloprost revealed that the patient’s PH included both group 3 and group 1 PH. This case suggests that a combination of exercise echocardiography and inhaled iloprost may be useful in distinguishing patients with systemic sclerosis-associated interstitial lung disease in whom group 1 and group 3 PH overlap. In addition, this method might also be useful for determining the therapeutic effects of iloprost.
No takes yet. Share an insight, caveat, or question.
Kinoshita et al. (2023) conducted a case report in Systemic sclerosis-associated interstitial lung disease with exercise-induced pulmonary hypertension (n=1). Inhaled iloprost was evaluated on Improvement in exercise-induced pulmonary hypertension on exercise echocardiography. Inhaled iloprost therapy improved exercise-induced pulmonary hypertension in a patient with systemic sclerosis-associated interstitial lung disease, as revealed by exercise echocardiography.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: